Trial Profile
Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms ComIT-1
- 13 Sep 2022 Results assessing toxicity, systemic responses and circulating tumor DNA (ctDNA) responses in patients with advanced NSCLC treated with atezolizumab and stereotactic body radiotherapy , presented at the 47th European Society for Medical Oncology Congress.
- 25 Mar 2021 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record
- 30 Aug 2018 New trial record